Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

25 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression/Transcription profiling by high throughput sequencing of TCF7L2 KD and control in INS1 832/13 cells

ABSTRACT: Genetic variants in TCF7L2 are the most highly associated variants with type 2 diabetes.We performed RNA_seq experiments on Control and Knockdown samples for 4 passages each. Library preparation was performed according to mRNA Sequening Sample Preparation Guide (illumina). Reagents were taken from the Illumina sample preparation kit v.2. Knockdown and control samples were sequenced together in one flowcell, 6 samples per lane. The aim of this study is to identify the downstream target genes that might the involvement of TCF7L2 in the development of type 2 diabetes. No technical replicate, 4 biological replicates.

INSTRUMENT(S): Illumina HiSeq 2000

ORGANISM(S): Rattus norvegicus

SUBMITTER: Yuedan Zhou

PROVIDER: E-MTAB-2034 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Effect of Tcf7l2 Knockout in the development and identity of Mouse brain Thalamus at embryonic stage E18.5 and P60

Project description:The thalamus of the brain acts as a relay station; taking inputs from several parts of the brain and then sending the information to the cortex and vice versa. It is also the structure know to affected in several brain developmental disorders such as schizophrenia, autism spectrum disorders, bipolar disorders etc. Upon in situ hybridisation one can visualise the expression of the transcription factor Tcf7l2 to be highest in prosomeric regions of the thalamus throughout development. With this information in mind we set out to find out, if the expression of Tcf7l2 is essential for the identity of the thalamic structure. Therefore, Tcf7l2 was knocked (KO) out using Cre+mice at embryonic stage E18.5 and postnatal adult stage P60. The E18.5 Tcf7l2 KO is a total knockout and the P60 Tcf7l2 KO is neuron-specific knockout. Total RNA was extracted and sent for sequencing using Illumina 2500. The data obtained was aligned by HISAT2 alignment tool, and the excon read counts were gathered using htseq counts, and expression normalization and differential gene expression was analysed using DESeq2.

2020-02-10 | E-MTAB-8755 | biostudies-arrayexpress

Chromatin occupancy and target genes of TCF7L2 in hepatocytes

Project description:TCF7L2 regulates multiple metabolic pathways in hepatocytes through a transcriptional network involving HNF4M-NM-1 For the identification of Tcf7l2 target genes using a RNA-seq timecourse, and for identifying the binding sites of Tcf7l2 and Hnf4a, Tcf7l2 was silenced in rat H4IIE hepatocytes using siRNA for Tcf7l2 with a scrambled siRNA as control. Treatment times for RNA-seq samples were 3, 6, 9, 12, 15, 18, 48, and 96 hours, and for ChIP-seq samples 15 h. RNA-seq timecourse was performed in duplicate or triplicate, and the ChIP-seq in duplicate for Tcf7l2 and in singlicate for Hnf4a. The H4IIE-specific transcriptome was defined from an independent set of pooled 24 h siRNA treated samples (N=3 for siRNA for Tcf7l2 and N=3 for scrambled siRNA).

2014-11-24 | E-GEOD-53862 | biostudies-arrayexpress

RNA-seq of mouse pancreatic pericytes from wild-type and Tcf7l2-mutated mice

Project description:To characterise their gene expression, wild type pancreatic pericytes were isolated based on the YFP-labeling from Nkx3.2-Cre;EYFP mice. As control, whole isolated islets were analysed.To identify Tcf7l2-depenedent genes, pancreatic pericytes were isolated from Nkx3.2-Cre;EYFP;Tcf7l2 flox/flox transgenic mice, and compared to wild type cells.

2017-12-14 | E-MTAB-5325 | biostudies-arrayexpress

Gene expression profiling of optic nerve from Tcf7l2 mutant and control mice

Project description:We performed gene expression pofiling of of optic nerve from Tcf7l2 mutant and control mice and identified significantly changed genes in mutant. RNA-seq of P12 optic nerve from control and mutant mice.

2016-02-19 | E-GEOD-65118 | biostudies-arrayexpress

Altering cancer transcriptomes using epigenomic inhibitors [RNA-Seq]

Project description:We have compared the genome-wide effects on the transcriptome after treatment with ICG-001 (the specific CBP inhibitor) versus C646, a compound that competes with acetyl-coA for the Lys-coA binding pocket of both CBP and p300. We found that both drugs cause large-scale changes in the transcriptome of HCT116 colon cancer cells and PANC1 pancreatic cancer cells, and reverse some tumor-specific changes in gene expression. Interestingly, although the epigenetic inhibitors affect cell cycle pathways in both the colon and pancreatic cancer cell lines, the WNT signaling pathway was affected only in the colon cancer cells. Notably, WNT target genes were similarly down-regulated after treatment of HCT116 with C646 as with ICG-001. To identify genes affected by direct targeting of a component of the transcriptional complex implicated in WNT regulation, we used siRNAs to knockdown TCF7L2 in PANC1 cells. Cells were treated with control siRNAs or siRNAs specific for TCF7L2 and RNA was analyzed by RNA-seq.

2015-01-07 | E-GEOD-63776 | biostudies-arrayexpress

Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3

Project description:The TCF7L2 transcription factor is linked to a variety of human diseases, including type 2 diabetes and cancer. One mechanism by which TCF7L2 could influence expression of genes involved in diverse diseases is by binding to distinct regulatory regions in different tissues. To test this hypothesis, we performed ChIP-seq for TCF7L2 in 6 human cell lines. We identified 116,000 non-redundant TCF7L2 binding sites, with only 1,864 sites common to the 6 cell lines. Using ChIP-seq, we showed that many genomic regions that are marked by both H3K4me1 and H3K27Ac are also bound by TCF7L2, suggesting that TCF7L2 plays a critical role in enhancer activity. Bioinformatic analysis of the cell type-specific TCF7L2 binding sites revealed enrichment for multiple transcription factors, including HNF4alpha and FOXA2 motifs in HepG2 cells and the GATA3 motif in MCF7 cells. ChIP-seq analysis revealed that TCF7L2 co-localizes with HNF4alpha and FOXA2 in HepG2 cells and with GATA3 in MCF7 cells. Interestingly, in MCF7 cells the TCF7L2 motif is enriched in most TCF7L2 sites but is not enriched in the sites bound by both GATA3 and TCF7L2. This analysis suggested that GATA3 might tether TCF7L2 to the genome at these sites. To test this hypothesis, we depleted GATA3 in MCF7 cells and showed that TCF7L2 binding was lost at a subset of sites. RNA-seq analysis suggested that TCF7L2 represses transcription when tethered to the genome via GATA3. Our studies demonstrate a novel relationship between GATA3 and TCF7L2, and reveal important insights into TCF7L2-mediated gene regulation. RNAseq analysis of MCF7 cells transfected with siCONTROL, siTCF7L2 or siGATA3. ChIP-seq analysis of H3K27ac, H3K4me1, H3K27me3, H3K9me3 in MCF7 cells; H3K4me1 and H3K27ac in HCT116 cells.

2012-06-05 | E-GEOD-38447 | biostudies-arrayexpress

Bulk RNASeq of mouse astrocytes isolated from the somatosensory cortex of control and Tcf7l2 conditional knockout (TdTomato+).

Project description:The aim of the experiment was to explain the role of astrocytic TCF7L2 transcription factor in astrocyte development and maturation. To do that we used Tcf7l2FL/FL:TdTomatoFL/FL animals with loxP sites that flanked exon 6, the deletion of which causes a frameshift mutation and leads to nonsense-mediated decay. Those mice were crossed with Aldh1l1Cre-ERT2 animals, that carried a transgene with tamoxifen-inducible Cre recombinase under the control of an astrocyte lineage-specific promoter. Control line was obtained crossing Aldh1l1Cre-ERT2 with Tcf7l2WT/WT:TdTomatoFL/FL animals. Tamoxifen (75 mg/kg body weight) was administered on postnatal day 6 and 8, 27 days later, (postnatal day 35), mice were sacrificed and TdT postive astrocytes were FACS-sorted using BD FACSAria, RNA from 4 control TdT and 3 Tcf7l2 cKO TdT mice were isolated and bulk RNA-seq was performed.

2024-06-28 | E-MTAB-13153 | biostudies-arrayexpress

Ribosomal protein S6 Rps6 heterozygous null deletion effect on footpad epidermis

Project description:Mutant and non-mutant footpad. McGowan et al. in press Keywords: Mutant vs. non-mutant The tissue (footpad epidermis) is from a conditional heterozygous null deletion of Rps6. One copy of Rps6 was deleted from keratinocytes in the skin using the K5.Cre transgene. K5Cre x Rps6^loxP

2008-06-12 | E-GEOD-11331 | biostudies-arrayexpress

Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand

Project description:Most studies on TCF7L2 SNP variants in the pathogenesis of type 2 diabetes (T2D) focus on a role of the encoded transcription factor TCF4 in Î²-cells. Here, a mouse genetics approach shows that removal of TCF4 from Î²-cells does not affect their function, while manipulating TCF4 levels in the liver has major effects on metabolism. In Tcf7l2-/- mice, the immediate postnatal surge in liver metabolism does not occur. Consequently, pups die due to hypoglycemia. Combining chromatin immunoprecipitation with gene expression profiling, we identify a TCF4-controlled metabolic gene program that is acutely activated in the postnatal liver. In concordance, adult liver-specific Tcf7l2 knockout mice show reduced hepatic glucose production during fasting and display improved glucose homeostasis when maintained on high-fat diet. Furthermore, liver-specific TCF4 overexpression increases hepatic glucose production. These observations imply that TCF4 directly activates metabolic genes, and that inhibition of Wnt signaling may be beneficial in metabolic disease. RNA was extracted from liver tissues of the Tcf7l2 wildtype or knockout mice with treatments as indicated. Microarray analysis was performed to compare the expression profile changes between Tcf7l2 knockout and wildtype mice in response to treatment.

2012-11-01 | E-GEOD-41284 | biostudies-arrayexpress

Statin therapy inhibits Fatty Acid Synthase via dynamic protein modifications

Project description:Recent discoveries revealed HMG-CoA is a reactive metabolite that can non-enzymatically modify proteins and impact their activity. Therefore, we predicted that inhibition of HMGCR by statins might increase HMG-CoA levels and protein modifications. Upon statin treatment, we observed a strong increase in HMG-CoA levels, and only a single protein was modified. Mass spectrometry revealed fatty acid synthase (FAS) was modified on active site residues and, importantly, the modification is located on non-lysine side-chains.

2022-05-20 | PXD030952 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data